Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)]

Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, French LE, Heinzerling L (2025)

Publication Type: Journal article, Erratum

Publication year: 2025

Journal

European Journal of Cancer Elsevier

Article Number: 115236

DOI: 10.1016/j.ejca.2025.115236

Abstract

The authors regret, that there is an error in the legend of “Long-term irAEs” in Fig. 1B: instead of "Long-term irAEs (3 weeks to <12 months since last ICI administration)", it should be "Long-term irAEs (12 weeks to <12 months since last ICI administration)". The underlying analyses are correct. Corrected version: [Figure presented] Fig. 1. Outpatient ICI-cohort (n = 147): Prevalence of persistent irAEs A) by time since last ICI administration and B) by type and time since last ICI administration with proportions and numbers of affected patients to all patients in the respective time periods. IrAE, immune-related adverse event; ICI, immune checkpoint inhibitor; CN, cranial nerve. Original, incorrect version: [Figure presented] Fig. 1. Outpatient ICI-cohort (n = 147): Prevalence of persistent irAEs A) by time since last ICI administration and B) by type and time since last ICI administration with proportions and numbers of affected patients to all patients in the respective time periods. IrAE, immune-related adverse event; ICI, immune checkpoint inhibitor; CN, cranial nerve.

Involved external institutions

Klinikum der Universität München DE Germany (DE) Klinikum Bremerhaven-Reinkenheide DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Schulz, T.U., Zierold, S., Sachse, M.M., Pesch, G., Tomsitz, D., Schilbach, K.,... Heinzerling, L. (2025). Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)]. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115236

MLA:

Schulz, Thomas U., et al. "Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)]." European Journal of Cancer (2025).

BibTeX: Download